ut-logo website  
 
Log in
Express registration and login!
If you have a Facebook or LinkedIN account, use one of the buttons on the left to either login or create a new account.

Log in

 

You are here:
Home

MDV3100:

1. Treatment of Castration Resistant Prostate Cancer
... and postdocetaxel settings. Targeted Therapies-Androgen Receptor Modulation Enzalutamide (formerly MDV3100) is an investigational therapy in Phase 3 clinical development. Enzalutamide is the ...
2. FDA approves Xtandi (enzalutamide)
SILVER SPRING, MD USA (PRESS RELEASE) - August 31, 2012 The U.S. Food and Drug Administration today approved Xtandi (enzalutamide) to treat men with late-stage (metastatic) castration-resistant prostate ...
3. Successful treatment of advanced metastatic prostate cancer following chemotherapy based on molecular profiling, "Beyond the Abstract," by Charles E. Myers, MD
BERKELEY, CA (UroToday.com) - In a case described in our recently published paper, we were faced with choosing the best treatment for a patient with prostate cancer who had progressed through radical prostatectomy, ...
4. Post-docetaxel therapy in castration resistant prostate cancer - the forest is growing in the desert, "Beyond the Abstract," by Amelia Altavilla, MD and Roberto Iacovelli, MD
BERKELEY, CA (UroToday.com) - The current landscape of treatment of castration-resistant prostate cancer (CRPC) has recently changed. Until 2004, docetaxel[1] and androgen-deprivation therapy[2] were the ...
5. A review of emerging strategies for optimizing the clinical impact of immunotherapeutic agents in prostate cancer
BERKELEY, CA (UroToday.com) - The potential role of immunotherapy in the clinical management of malignancies has been debated for decades by researchers and medical oncologists.
6. Persistent androgen receptor-mediated transcription in castration-resistant prostate cancer under androgen-deprived conditions, "Beyond the Abstract," by Li Jia, PhD
BERKELEY, CA (UroToday.com) - Prostate cancer is fueled by the male sex hormone, or androgen, which interacts with a cellular receptor called androgen receptor (AR).